Nir Barzilai

Barzilai has articulated a recognizable geroscience vision: target aging itself, shift from disease treatment to health treatment, and develop practical pathways such as biomarkers, clinics/testbeds, and interventions like metformin. The evidence shows durable and specific direction, but it lacks a clear public destination statement, explicit timeline, or detailed end-state vision for ending/reversing aging, limiting the score below top-tier field-defining vision.

Primary citation metrics show very strong scientific influence: h-index 102, 40,606 total citations, and multiple highly cited papers directly tied to aging biology, metformin/aging, centenarians, metabolic pathways, and biomarkers. This supports a near field-defining scientific impact score, though not a perfect 10 because the evidence does not establish his exact contribution level on the most-cited multi-author works and includes no clinical-trial impact signal.

The supplied evidence supports Nir Barzilai's scientific activity and aging-research prominence, but does not show deployment of his own capital, philanthropy, investment capital, or institution-building resources toward longevity. Under the rubric, this appears inapplicable rather than merely low-scoring.

No evidence provided of personal capital deployment, donations, fund allocation, or resource-allocation activity; evidence describes him as a scientist/researcher.

Strategic_taste applies because there is at least one organizational bet and some evidence of a coherent scientific direction around metabolism, insulin, lipids, metformin, and aging. However, the provided evidence does not document a clear strategic thesis, timing, risk appetite, counterfactual importance, or rationale for CohBar, so the score should remain low despite Barzilai's broader prominence in aging research.

The dimension applies because there is evidence of organization creation, but the provided evidence only supports one founded company and no active organizations or donation-created programs. The independent/primary academic sources establish Barzilai as an aging researcher, but they do not corroborate broader field-building achievements such as creating durable programs, communities, protocols, or funding paths.

The dimension applies, but the provided evidence contains almost no direct support for public risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, or self-experimentation. Barzilai is clearly an influential longevity researcher with substantial scholarly output, including work on metformin and aging, but scientific productivity alone is not evidence of bravery or conviction under this rubric.

Barzilai shows credible second-order leverage through very high scholarly influence, participation in broad multi-institution geroscience consensus work, and founding CohBar. The evidence supports substantial field legitimacy and collaborator reach, but it is thin on concrete downstream outcomes such as capital attracted, policy change, talent pipelines, founders created, or follow-on projects directly attributable to him.